FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2522515855> ?p ?o ?g. }

• W2522515855 endingPage "580" @default.
• W2522515855 startingPage "575" @default.
• W2522515855 abstract "The introduction of antiretroviral therapy (ART) led to huge reductions in human immunodeficiency virus (HIV)-related deaths, turning HIV-infection into a chronic condition. Attention is now turning to quality of life for patients on lifelong ART treatment, reflecting on the safety of antiretroviral drugs. In sub-Saharan Africa, efavirenz (EFV) forms the preferred first-line ART but adverse drug events have also been reported. We express our concern on EFV-based regimens being part of mass rollout programs without full attention to toxicities. EFV is associated with various neuropsychiatric adverse events (AEs). If EFV use is not monitored, a huge burden of neuropsychiatric AEs and elevated risk of drug resistance due to nonadherence are likely to follow. A monumental EFV-based ART regimen rollout program, through the UNAIDS 90-90-90 and option B plus programs/approaches, is planned, which will more than double the number of patients on EFV-containing ART. According to this ambitious treatment target, by 2020, 90% of all people living with HIV will know their HIV status; 90% of all people with diagnosed HIV infection will receive sustained ART; and 90% of all people receiving ART will have viral suppression. On the other hand, HIV patients of African origin are predisposed to developing EFV-induced neuropsychiatric AEs due to specific CYP2B6 genetic variants causing impaired metabolism of EFV. It is our considered opinion that the potential quantitative and qualitative burden of EFV-induced neuropsychiatric AEs, which can vary from person-to-person and between populations, deserve special attention and action during the ART rollout program. We here make a case for Africa in particular where we project the burden of neuropsychiatric AEs to be greatest. We advocate for surveillance of neuropsychiatric AEs due to EFV therapy, incorporation of pharmacogenetics testing for CYP2B6 to assist in EFV dosing, and measurement of plasma EFV concentration, as a three-pronged rational therapeutic drug monitoring strategy to guide EFV treatment toward precision medicine." @default.
• W2522515855 created "2016-09-30" @default.
• W2522515855 creator A5047773727 @default.
• W2522515855 creator A5057172065 @default.
• W2522515855 creator A5069116936 @default.
• W2522515855 date "2016-10-01" @default.
• W2522515855 modified "2023-10-12" @default.
• W2522515855 title "Rolling out Efavirenz for HIV Precision Medicine in Africa: Are We Ready for Pharmacovigilance and Tackling Neuropsychiatric Adverse Effects?" @default.
• W2522515855 cites W1557291638 @default.
• W2522515855 cites W1910280141 @default.
• W2522515855 cites W1963795473 @default.
• W2522515855 cites W1975474872 @default.
• W2522515855 cites W1976243027 @default.
• W2522515855 cites W1998903052 @default.
• W2522515855 cites W2006103193 @default.
• W2522515855 cites W2007358452 @default.
• W2522515855 cites W2011912864 @default.
• W2522515855 cites W2018959477 @default.
• W2522515855 cites W2036350240 @default.
• W2522515855 cites W2037631311 @default.
• W2522515855 cites W2039897959 @default.
• W2522515855 cites W2042867111 @default.
• W2522515855 cites W2045143041 @default.
• W2522515855 cites W2058207881 @default.
• W2522515855 cites W2059157689 @default.
• W2522515855 cites W2067495470 @default.
• W2522515855 cites W2072794337 @default.
• W2522515855 cites W2081686997 @default.
• W2522515855 cites W2093607705 @default.
• W2522515855 cites W2094815437 @default.
• W2522515855 cites W2099354741 @default.
• W2522515855 cites W2099746597 @default.
• W2522515855 cites W2105967765 @default.
• W2522515855 cites W2106737113 @default.
• W2522515855 cites W2110868212 @default.
• W2522515855 cites W2116356899 @default.
• W2522515855 cites W2116403346 @default.
• W2522515855 cites W2122516616 @default.
• W2522515855 cites W2126125949 @default.
• W2522515855 cites W2136381344 @default.
• W2522515855 cites W2138587985 @default.
• W2522515855 cites W2141275708 @default.
• W2522515855 cites W2147458465 @default.
• W2522515855 cites W2148303082 @default.
• W2522515855 cites W2152347011 @default.
• W2522515855 cites W2173347118 @default.
• W2522515855 cites W2252575358 @default.
• W2522515855 cites W2253998502 @default.
• W2522515855 cites W2293382714 @default.
• W2522515855 cites W2313132761 @default.
• W2522515855 cites W2313885872 @default.
• W2522515855 cites W2319448660 @default.
• W2522515855 cites W2323214475 @default.
• W2522515855 cites W2473282899 @default.
• W2522515855 cites W1081891785 @default.
• W2522515855 doi "https://doi.org/10.1089/omi.2016.0120" @default.
• W2522515855 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27627692" @default.
• W2522515855 hasPublicationYear "2016" @default.
• W2522515855 type Work @default.
• W2522515855 sameAs 2522515855 @default.
• W2522515855 citedByCount "26" @default.
• W2522515855 countsByYear W25225158552017 @default.
• W2522515855 countsByYear W25225158552018 @default.
• W2522515855 countsByYear W25225158552019 @default.
• W2522515855 countsByYear W25225158552020 @default.
• W2522515855 countsByYear W25225158552021 @default.
• W2522515855 countsByYear W25225158552022 @default.
• W2522515855 countsByYear W25225158552023 @default.
• W2522515855 crossrefType "journal-article" @default.
• W2522515855 hasAuthorship W2522515855A5047773727 @default.
• W2522515855 hasAuthorship W2522515855A5057172065 @default.
• W2522515855 hasAuthorship W2522515855A5069116936 @default.
• W2522515855 hasConcept C118552586 @default.
• W2522515855 hasConcept C126322002 @default.
• W2522515855 hasConcept C142462285 @default.
• W2522515855 hasConcept C159110408 @default.
• W2522515855 hasConcept C177713679 @default.
• W2522515855 hasConcept C197934379 @default.
• W2522515855 hasConcept C203014093 @default.
• W2522515855 hasConcept C2779130552 @default.
• W2522515855 hasConcept C2779951463 @default.
• W2522515855 hasConcept C2781413609 @default.
• W2522515855 hasConcept C2781432083 @default.
• W2522515855 hasConcept C2993143319 @default.
• W2522515855 hasConcept C3013748606 @default.
• W2522515855 hasConcept C57658597 @default.
• W2522515855 hasConcept C71924100 @default.
• W2522515855 hasConcept C98274493 @default.
• W2522515855 hasConceptScore W2522515855C118552586 @default.
• W2522515855 hasConceptScore W2522515855C126322002 @default.
• W2522515855 hasConceptScore W2522515855C142462285 @default.
• W2522515855 hasConceptScore W2522515855C159110408 @default.
• W2522515855 hasConceptScore W2522515855C177713679 @default.
• W2522515855 hasConceptScore W2522515855C197934379 @default.
• W2522515855 hasConceptScore W2522515855C203014093 @default.
• W2522515855 hasConceptScore W2522515855C2779130552 @default.
• W2522515855 hasConceptScore W2522515855C2779951463 @default.
• W2522515855 hasConceptScore W2522515855C2781413609 @default.

• next